Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)

X
Trial Profile

Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Post-HERCULES
  • Sponsors Ablynx; Sanofi
  • Most Recent Events

    • 13 Dec 2022 Results of post hoc analysis (from two studies HERCULES and post-HERCULES) assessing the efficacy and safety of caplacizumab in patients with iTTP presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 22 Sep 2022 Results assessing long-term outcomes of patients with immune-mediated thrombotic thrombocytopenic purpura with caplacizumab, published in the Journal of Thrombosis and Haemostasis.
    • 17 Jun 2022 Results assessing long-term safety and efficacy of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura, and safety and efficacy of repeated caplacizumab use for acquired thrombotic thrombocytopenic purpura recurrence, presented at the 27th Congress of the European Haematology Association.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top